Retinopathy clinical trials

Explore recruiting retinopathy clinical trials.

Recruiting retinopathy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Retinopathy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

(Neo)adjuvant IDE196 (Darovasertib) in Patients with Localized Ocular Melanoma

Italy, France, Netherlands, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes (FOCUS)

Portugal, Poland, Spain, Romania, Czechia, Germany +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

PHase 3, Multicenter, RandOmized, Double-masked, PlacEbo-CoNtrolled Study of TInlarebant to EXplore Safety and Efficacy in the Treatment of Geographic Atrophy (the PHOENIX Study)

Czechia, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase 1, open-label trial in healthy subjects and in subjects with diabetes investigating pharmacokinetics, tolerability, safety, and food effect following single and multiple dosing of danegaptide

Sweden

Human Pharmacology (Phase I)- Other EU CTIS Study details

Phase I, single and multiple ascending dose, randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the safety, tolerability and pharmacokinetics of topical ocular administration of DS101 in healthy subjects.

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A multicentric, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of COLIRIOBCN070660 administered topically in patients with moderately severe to severe non-proliferative diabetic retinopathy

Spain

Phase II and Phase III (Integrated) EU CTIS Study details

Retinopathy trials by city

Retinopathy in Toronto Retinopathy in Vancouver Retinopathy in Montreal Retinopathy in Calgary Retinopathy in Edmonton Retinopathy in Ottawa Retinopathy in Winnipeg Retinopathy in Quebec City Retinopathy in Hamilton Retinopathy in Kitchener Retinopathy in London Retinopathy in Halifax Retinopathy in New York Retinopathy in Los Angeles Retinopathy in Chicago Retinopathy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease